FDA warned VivioMD that its website misbrands compounded semaglutide and tirzepatide by implying VivioMD is the compounder.
What happened
FDA reviewed VivioMD’s website, https://viviomd.com, in March 2026 and found it offered compounded semaglutide and tirzepatide products. FDA said the pictured labels identify “VivioMD,” suggesting VivioMD is the compounder when it is not, and that this makes the products misbranded.
What FDA found
The website shows compounded semaglutide and tirzepatide labels with “VivioMD,” implying VivioMD made the drugs when it did not.
FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)FDA says the advertising or promotion of these compounded drugs is false or misleading for the same reason.
FD&C Act § 502(bb) [21 U.S.C. § 352(bb)]Because the drugs are misbranded, introducing them into interstate commerce is a prohibited act.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells VivioMD to send a written response to CDER’s Office of Compounding Quality and Compliance within 15 business days. The response must include corrective steps, identify the entities that produce the compounded drugs, provide sample labeling, and address other website claims.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounders whose products are marketed by third-party websites
- brands and marketers that label or advertise compounded drugs
This is a summary. Read the original letter on fda.gov.